Extended Lymphadenectomy for Gastric Cancer in the Neoadjuvant Era: Current Status, Clinical Implications and Contentious Issues

• Published in: Current oncology (Toronto) 2023-01, Vol.30 (1), p.875-896
• Main Authors: Marano, Luigi, Carbone, Ludovico, Poto, Gianmario Edoardo, Restaino, Valeria, Piccioni, Stefania Angela, Verre, Luigi, Roviello, Franco, Marrelli, Daniele
• Format: Article
• Language: English
• Subjects: gastric cancer; Humans; Lymph Node Excision; lymphadenectomy; neoadjuvant; Neoadjuvant Therapy; Neoplasm Recurrence, Local - surgery; Prognosis; Review; Stomach Neoplasms - drug therapy; Stomach Neoplasms - pathology; Stomach Neoplasms - surgery
• ISSN: 1718-7729; 1198-0052; 1718-7729
• DOI: 10.3390/curroncol30010067

Despite its decreasing incidence, gastric cancer remains an important global healthcare problem due to its overall high prevalence and high mortality rate. Since the MAGIC and FNLCC/FFCD trials, the neoadjuvant chemotherapy has been recommended throughout Europe in gastric cancer. Potential benefits of preoperative treatments include a higher rate of R0 resection achieved by downstaging the primary tumor, a likely effect on micrometastases and isolated tumor cells in the lymph nodes, and, as a result, improved cancer-related survival. Nevertheless, distortion of anatomical planes of dissection, interstitial fibrosis, and sclerotic tissue changes may increase surgical difficulty. The collection of at least twenty-five lymph nodes after neoadjuvant therapy would seem to ensure removal of undetectable node metastasis and reduce the likelihood of locoregional recurrence. It is not what you take but what you leave behind that defines survival. Therefore, para-aortic lymph node dissection is safe and effective after neoadjuvant chemotherapy, in both therapeutic and prophylactic settings. In this review, the efficacy of adequate lymph node dissection, also in a neoadjuvant setting, has been investigated in the key studies conducted to date on the topic.